The Function and Prognostic Significance of Cripto-1 in Colorectal Cancer

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Bosetti C, Levi F, Rosato V, Bertuccio P, Lucchini F, Negri E, La Vecchia C. Recent trends in colorectal cancer mortality in Europe. Int J Cancer. 2011;129(1):180–191. doi:10.1002/ijc.25653.
   PubMed Web of Science ®Google Scholar
• Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual Report to the Nation on the Status of Cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–573. doi:10.1002/cncr.24760.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Colorectal cancer facts & figures 2014–2016. Atlanta: American Cancer Society; 2014.
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342. doi:10.1056/NEJMoa032691.
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–2048. doi:10.1056/NEJMoa071834.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. JCO. 2007;25(13):1658–1664. doi:10.1200/JCO.2006.08.1620.
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. JCO. 2008;26(10):1626–1634. doi:10.1200/JCO.2007.14.7116.
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–1765. doi:10.1056/NEJMoa0804385.
   PubMed Web of Science ®Google Scholar
• Dono R, Montuori N, Rocchi M, De Ponti-Zilli L, Ciccodicola A, Persico MG. Isolation and characterization of the CRIPTO autosomal gene and its X-linked related sequence. Am J Hum Genet. 1991;49(3):555–565.
   PubMed Web of Science ®Google Scholar
• Ciccodicola A, Dono R, Obici S, Simeone A, Zollo M, Persico MG. Molecular characterization of a gene of the ‘EGF family’ expressed in undifferentiated human NTERA2 teratocarcinoma cells. Embo J. 1989;8(7):1987–1991. doi:10.1002/j.1460-2075.1989.tb03605.x.
   PubMed Web of Science ®Google Scholar
• Minchiotti G, Parisi S, Liguori G, Signore M, Lania G, Adamson ED, et al. Membrane-anchorage of Cripto protein by glycosylphosphatidylinositol and its distribution during early mouse development. Mech Dev. 2000;90(2):133–142. doi:10.1016/S0925-4773(99)00235-X.
   PubMed Web of Science ®Google Scholar
• Xu C, Liguori G, Persico MG, Adamson ED. Abrogation of the Cripto gene in mouse leads to failure of postgastrulation morphogenesis and lack of differentiation of cardiomyocytes. Development. 1999;126(3):483–494.
   PubMed Web of Science ®Google Scholar
• Minchiotti G. Nodal-dependant Cripto signaling in ES cells: from stem cells to tumor biology. Oncogene. 2005;24(37):5668–5675. doi:10.1038/sj.onc.1208917.
   PubMed Web of Science ®Google Scholar
• Saeki T, Stromberg K, Qi CF, Gullick WJ, Tahara E, Normanno N, et al. Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. Cancer Res. 1992;52(12):3467–3473.
   PubMed Web of Science ®Google Scholar
• Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, et al. Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res. 2006;12(17):5158–5164. doi:10.1158/1078-0432.CCR-06-0274.
   PubMed Web of Science ®Google Scholar
• Byrne RL, Autzen P, Birch P, Robinson MC, Gullick WJ, Neal DE, Hamdy FC. The immunohistochemical detection of cripto-1 in benign and malignant human bladder. J Pathol. 1998;185(1):108–111. doi:10.1002/(SICI)1096-9896(199805)185:1<108::AID-PATH51>3.0.CO;2-M.
   PubMed Web of Science ®Google Scholar
• Bianco C, Strizzi L, Normanno N, Khan N, Salomon DS. Cripto-1: an oncofetal gene with many faces. Curr Top Dev Biol. 2005;67:85–133. doi:10.1016/S0070-2153(05)67003-2.
   PubMed Web of Science ®Google Scholar
• Strizzi L, Bianco C, Normanno N, Salomon D. Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene. 2005;24(37):5731–5741. doi:10.1038/sj.onc.1208918.
   PubMed Web of Science ®Google Scholar
• Zhong XY, Zhang LH, Jia SQ, Shi T, Niu ZJ, Du H, et al. Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer. Histopathology. 2008;52(5):560–568. doi:10.1111/j.1365-2559.2008.02971.x.
   PubMed Web of Science ®Google Scholar
• Gong YP, Yarrow PM, Carmalt HL, Kwun SY, Kennedy CW, Lin BP, et al. Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival. Eur J Surg Oncol. 2007;33(4):438–443. doi:10.1016/j.ejso.2006.10.014.
   PubMed Web of Science ®Google Scholar
• Wang JH, Wei W, Xu J, Guo ZX, Xiao CZ, Zhang YF, et al. Elevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinoma. Oncotarget. 2015;6:35116–35128. doi:10.18632/oncotarget.5057.
   PubMedGoogle Scholar
• Tysnes BB, Saetran HA, Mørk SJ, Margaryan NV, Eide GE, Petersen K, et al. Age-dependent association between protein expression of the embryonic stem cell marker Cripto-1 and survival of glioblastoma patients. Trans Onc. 2013;6(6):732–741. doi:10.1593/tlo.13427.
   PubMed Web of Science ®Google Scholar
• Miyoshi N, Ishii H, Mimori K, Sekimoto M, Doki Y, Mori M. TDGF1 is a novel predictive marker for metachronous metastasis of colorectal cancer. Int J Oncol. 2010;36:563–568. doi:10.3892/ijo_00000530.
   PubMed Web of Science ®Google Scholar
• Bianco C, Rangel MC, Castro NP, Nagaoka T, Rollman K, Gonzales M, et al. Role of Cripto-1 in stem cell maintenance and malignant progression. Am J Pathol. 2010;177(2):532–540. doi:10.2353/ajpath.2010.100102.
   PubMed Web of Science ®Google Scholar
• Chang-Yeol Yeo CY, Whitman M. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Molecular Cell. 2001;7:949–957. doi:10.1016/S1097-2765(01)00249-0.
   PubMed Web of Science ®Google Scholar
• Bianco C, Adkins HB, Wechselberger C, Seno M, Normanno N, De Luca A, et al. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. Mol Cell Biol. 2002;22(8):2586–2597. doi:10.1128/MCB.22.8.2586-2597.2002.
   PubMed Web of Science ®Google Scholar
• Kannan S, De Santis M, Lohmeyer M, Riese DJ, 2nd, Smith GH, Hynes N, et al. Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem. 1997;272(6):3330–3335. doi:10.1074/jbc.272.6.3330.
   PubMed Web of Science ®Google Scholar
• Bianco C, Kannan S, De Santis M, Seno M, Tang CK, Martinez-Lacaci I, et al. Cripto-1 indirectly stimulates the tyrosine phosphorylation of erb B-4 through a novel receptor. J Biol Chem. 1999;274(13):8624–8629. doi:10.1074/jbc.274.13.8624.
   PubMed Web of Science ®Google Scholar
• Ebert AD, Wechselberger C, Frank S, Wallace-Jones B, Seno M, Martinez-Lacaci I, et al. Cripto-1 induces phosphatidylinositol 3 ‘-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3 beta in human cervical carcinoma cells. Cancer Res. 1999;59:4502–4505.
   PubMed Web of Science ®Google Scholar
• Mancino M, Strizzi L, Wechselberger C, Watanabe K, Gonzales M, Hamada S, et al. Regulation of human Cripto-1 gene expression by TGF-beta1 and BMP-4 in embryonal and colon cancer cells. J Cell Physiol. 2008;215(1):192–203. doi:10.1002/jcp.21301.
   PubMed Web of Science ®Google Scholar
• Francescangeli F, Contavalli P, De Angelis ML, Baiocchi M, Gambara G, Pagliuca A, et al. Dynamic regulation of the cancer stem cell compartment by Cripto-1 in colorectal cancer. Cell Death Differ. 2015;22(10):1700–1713. doi:10.1038/cdd.2015.19.
   PubMed Web of Science ®Google Scholar
• Qi CF, Liscia DS, Normanno N, Merlo G, Johnson GR, Gullick WJ, et al. Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer. 1994;69(5):903–910. doi:10.1038/bjc.1994.174.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Miura K, Horii A, Kaneko N, Fujibuchi W, Kiseleva L, et al. Orthotopic implantation mouse model and cDNA microarray analysis indicates several genes potentially involved in lymph node metastasis of colorectal cancer. Cancer Sci. 2008;99(4):711–719. doi:10.1111/j.1349-7006.2008.00725.x.
   PubMed Web of Science ®Google Scholar
• Xu CH, Wang Y, Qian LH, Yu LK, Zhang XW, Wang QB. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis. Clin Respir J. 2017;11(6):765–771. doi:10.1111/crj.12414.
   Web of Science ®Google Scholar
• Wu Z, Li G, Wu L, Weng D, Li X, Yao K. Cripto-1 overexpression is involved in the tumorigenesis of nasopharyngeal carcinoma. BMC Cancer. 2009;9(1):315. doi:10.1186/1471-2407-9-315.
   PubMedGoogle Scholar
• Castro NP, Fedorova-Abrams ND, Merchant AS, Rangel MC, Nagaoka T, Karasawa H, et al. Cripto-1 as a novel therapeutic target for triple negative breast cancer. Oncotarget. 2015;6(14):11910–11929. doi:10.18632/oncotarget.4182.
   PubMedGoogle Scholar
• De Luca A, Lamura L, Strizzi L, Roma C, D'Antonio A, Margaryan N, et al. Expression and functional role of CRIPTO-1 in cutaneous melanoma. Br J Cancer. 2011;105(7):1030–1038. doi:10.1038/bjc.2011.324.
   PubMed Web of Science ®Google Scholar
• Cespedes MV, Espina C, Garcia-Cabezas MA, Trias M, Boluda A, Gomez del Pulgar MT, et al. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol. 2007;170:1077–1085. doi:10.2353/ajpath.2007.060773.
   PubMed Web of Science ®Google Scholar
• Nagaoka T, Karasawa H, Castro NP, Rangel MC, Salomon DS, Bianco C. An evolving web of signaling networks regulated by Cripto-1. Growth Factors. 2012;30(1):13–21. doi:10.3109/08977194.2011.641962.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006;46(1):249–279. doi:10.1016/j.advenzreg.2006.01.004.
   PubMedGoogle Scholar
• Shani G, Fischer WH, Justice NJ, Kelber JA, Vale W, Gray PC. GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth. Mol Cell Biol. 2008;28(2):666–677. doi:10.1128/MCB.01716-07.
   PubMed Web of Science ®Google Scholar
• Kelber JA, Panopoulos AD, Shani G, Booker EC, Belmonte JC, Vale WW, et al. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene. 2009;28(24):2324–2336. doi:10.1038/onc.2009.97.
   PubMed Web of Science ®Google Scholar
• Spike BT, Kelber JA, Booker E, Kalathur M, Rodewald R, Lipianskaya J, et al. CRIPTO/GRP78 signaling maintains fetal and adult mammary stem cells ex vivo. Stem Cell Rep . 2014;2(4):427–439. doi:10.1016/j.stemcr.2014.02.010.
   PubMed Web of Science ®Google Scholar
• Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions. Febs Lett. 1997;410(1):83–86. doi:10.1016/S0014-5793(97)00412-2.
   PubMed Web of Science ®Google Scholar
• Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol. 1999;19(10):6845–6857. doi:10.1128/MCB.19.10.6845.
   PubMed Web of Science ®Google Scholar
• Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med. 2011;154(1):37–49. doi:10.7326/0003-4819-154-1-201101040-00006.
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–762. doi:10.1016/S1470-2045(10)70130-3.
   PubMed Web of Science ®Google Scholar
• Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol. 2016;27(9):1746–1753. doi:10.1093/annonc/mdw261.
   PubMed Web of Science ®Google Scholar
• Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013;2(9):e71–e71. doi:10.1038/oncsis.2013.35.
   PubMedGoogle Scholar
• Liu R, Li X, Gao W, Zhou Y, Wey S, Mitra SK, et al. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clin Cancer Res. 2013;19(24):6802–6811. doi:10.1158/1078-0432.CCR-13-1106.
   PubMed Web of Science ®Google Scholar
• Wang CY, Guo ST, Wang JY, Liu F, Zhang YY, Yari H, Yan XG, et al. Inhibition of HSP90 by AUY922 preferentially kills mutant KRAS colon cancer cells by activating Bim through ER stress. Mol Cancer Ther. 2016;15(3):448–459. doi:10.1158/1535-7163.MCT-15-0778.
   PubMed Web of Science ®Google Scholar